InsiderSignalSign in

← Insider buys

Clay B Siegall has bought stock on 9 days since May 2024

Director at Shattuck Labs, Inc., and 3 other companies

SEC CIK 0001167496 · Filings on SEC.gov ↗

$6.5MBought

$193.5MSold

Jun 11Last buy

Clay B Siegall's record

3 months after each buy, from the first price a copier could get.

−0.2%Average

−1.8 ptsVs S&P 500

4 of 9Higher

9 buys since 2024 with 3 months of prices.

Companies

Every filing

99 filings since Mar 2016, newest first

Seattle Genetics Inc /wa

President and CEO

$1.4M−3.0%Jun 12

Seattle Genetics Inc /wa

President and CEO

$1.4M−3.0%May 10

Seattle Genetics Inc /wa

President and CEO

$1.6M−3.0%Apr 10

Seattle Genetics Inc /wa

President and CEO

$1.4M−3.0%Mar 12

Seattle Genetics Inc /wa

Insider

$1.3M−3.0%Feb 12

Seattle Genetics Inc /wa

President and CEO

$1.3M−3.0%Jan 10

Seattle Genetics Inc /wa

President and CEO

$1.2M−3.0%Dec 12

Seattle Genetics Inc /wa

President and CEO

$1.2M−3.0%Nov 9

Seattle Genetics Inc /wa

President and CEO

$1.6M−3.0%Oct 9

Seattle Genetics Inc /wa

President and CEO

$1.5M−3.0%Sep 19

Seattle Genetics Inc /wa

President and CEO

$1.9M−4.0%Aug 29

Seattle Genetics Inc /wa

President and CEO

$1.9M−4.0%Aug 23

Seattle Genetics Inc /wa

Insider

$1.4M−3.0%Aug 13

Seattle Genetics Inc /wa

President and CEO

$1.3M−3.0%Jul 11

Seattle Genetics Inc /wa

President and CEO

$1.2M−3.0%Jun 12

Seattle Genetics Inc /wa

President and CEO

$1.0M−3.0%May 11

Seattle Genetics Inc /wa

President and CEO

$951K−3.0%Apr 11

Seattle Genetics Inc /wa

President and CEO

$1.1M−3.0%Mar 13

Seattle Genetics Inc /wa

President and CEO

$937K−3.0%Feb 13

Seattle Genetics Inc /wa

President and CEO

$974K−3.0%Jan 16

Seattle Genetics Inc /wa

President and CEO

$1.0M−3.0%Dec 13

Seattle Genetics Inc /wa

President and CEO

$1.1M−3.0%Nov 14

Seattle Genetics Inc /wa

President and CEO

$1.2M−3.0%Oct 13

Seattle Genetics Inc /wa

President and CEO

$1.0M−3.0%Sep 12

Seattle Genetics Inc /wa

President and CEO

$1.2M−4.0%Aug 30

Seattle Genetics Inc /wa

President and CEO

$509K−2.0%Aug 9

Seattle Genetics Inc /wa

President and CEO

$542K−2.0%Jul 7

Seattle Genetics Inc /wa

President and CEO

$680K−2.0%Jun 7

Seattle Genetics Inc /wa

President and CEO

$893K−2.0%May 9

Seattle Genetics Inc /wa

President and CEO

$911K−2.0%Apr 6

Seattle Genetics Inc /wa

President and CEO

$984K−2.0%Mar 8

Seattle Genetics Inc /wa

President and CEO

$890K−2.0%Feb 8

Seattle Genetics Inc /wa

President and CEO

$837K−2.0%Jan 10

Seattle Genetics Inc /wa

President and CEO

$957K−2.0%Dec 8

Seattle Genetics Inc /wa

President and CEO

$845K−2.0%Nov 9

Seattle Genetics Inc /wa

President and CEO

$787K−2.0%Oct 11

Seattle Genetics Inc /wa

President and CEO

$1.6M−5.0%Sep 12

Seattle Genetics Inc /wa

President and CEO

$529K−2.0%Sep 8

Seattle Genetics Inc /wa

President and CEO

$1.1M−4.0%Aug 22

Seattle Genetics Inc /wa

President and CEO

$550K−2.0%Aug 10

Seattle Genetics Inc /wa

President and CEO

$183K−1.0%Jul 29

Seattle Genetics Inc /wa

President and CEO

$309K−1.0%Jul 7

Seattle Genetics Inc /wa

President and CEO

$963K−4.0%Jun 8

Seattle Genetics Inc /wa

President and CEO

$2.0M−8.0%May 27

Seattle Genetics Inc /wa

President and CEO

$337K−1.0%May 25

Seattle Genetics Inc /wa

President and CEO

$268K−1.0%May 19

Seattle Genetics Inc /wa

President and CEO

Seattle Genetics Inc /wa

President and CEO

$275K−1.0%Apr 7

Seattle Genetics Inc /wa

President and CEO

$541K−3.0%Mar 23

About Clay B Siegall

Clay B. Siegall, Ph.D., is a biopharmaceutical executive and scientist who serves as a director of Shattuck Labs, Inc. (Nasdaq: STTK) and has recently reported open‑market purchases of Shattuck Labs stock as a corporate insider.( He joined Shattuck’s board of directors effective March 1, 2024, bringing extensive oncology drug-development and leadership experience to the clinical‑stage biotechnology company.( In a June 2026 underwritten offering, Siegall bought 62,500 shares of Shattuck Labs common stock at $4.00 per share, increasing his direct holdings to 318,608 shares.(

Siegall is the President, Chief Executive Officer, and Chairman of the Board of Immunome, Inc. (Nasdaq: IMNM), where he has led significant equity financings and oversees development of targeted oncology therapies.( He is best known as the founder and former CEO, president, and chairman of Seagen Inc. (formerly Seattle Genetics), which he co‑founded in 1998 and built into a leader in antibody‑drug conjugate (ADC) cancer therapies, including multiple FDA‑approved medicines.( Over a 25+ year career in the biopharmaceutical industry, he has also held senior or board roles at companies such as Morphimmune, Tourmaline Bio, Ultragenyx Pharmaceutical, and others.( A trained scientist, Siegall has authored more than 70 publications, holds numerous patents, and earned a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.